{"id":611309,"date":"2022-08-09T17:46:01","date_gmt":"2022-08-09T17:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=611309"},"modified":"2022-08-09T17:46:01","modified_gmt":"2022-08-09T17:46:01","slug":"pyelonephritis-therapeutic-analysis-insights-into-fda-and-eu-approvals-clinical-trials-latest-breakthroughs-emerging-therapies-and-key-companies-bayer-venatorx-nabriva-spero-shionogi","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pyelonephritis-therapeutic-analysis-insights-into-fda-and-eu-approvals-clinical-trials-latest-breakthroughs-emerging-therapies-and-key-companies-bayer-venatorx-nabriva-spero-shionogi_611309.html","title":{"rendered":"Pyelonephritis Therapeutic Analysis | Insights Into FDA And EU Approvals, Clinical Trials, Latest Breakthroughs, Emerging Therapies, And Key Companies &#8211; Bayer, Venatorx, Nabriva, Spero, Shionogi"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1660019298.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pyelonephritis Therapeutic Analysis | Insights Into FDA And EU Approvals, Clinical Trials, Latest Breakthroughs, Emerging Therapies, And Key Companies - Bayer, Venatorx, Nabriva, Spero, Shionogi\" src=\"https:\/\/www.abnewswire.com\/uploads\/1660019298.jpeg\" alt=\"Pyelonephritis Therapeutic Analysis | Insights Into FDA And EU Approvals, Clinical Trials, Latest Breakthroughs, Emerging Therapies, And Key Companies - Bayer, Venatorx, Nabriva, Spero, Shionogi\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Pyelonephritis Therapeutics<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><em>As per DelveInsight, the Pyelonephritis Market dynamics is expected to transform in the coming years owing to the expected launch of the therapies. The increasing awareness related to urinary tract infections including pyelonephritis will also boost the pyelonephritis market growth.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;<strong>Pyelonephritis Pipeline Insight, 2022&Prime;<\/strong>&nbsp;report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pyelonephritis Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The&nbsp;<strong>Pyelonephritis Pipeline report<\/strong>&nbsp;embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d4301eac5865d166528e5201606f3001.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pyelonephritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Pyelonephritis Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the&nbsp;<strong>treatment of Pyelonephritis<\/strong>&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for&nbsp;<strong>Pyelonephritis Treatment<\/strong>.<\/li>\n<li><strong>Pyelonephritis key companies<\/strong>&nbsp;involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li><strong>Pyelonephritis Drugs<\/strong>&nbsp;under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the&nbsp;<strong>Pyelonephritis market<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pyelonephritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pyelonephritis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pyelonephritis Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the&nbsp;Pyelonephritis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Spero Therapeutics<\/li>\n<li>Shionogi<\/li>\n<li>Allecra Therapeutics<\/li>\n<li>VenatoRx Pharmaceuticals<\/li>\n<li>Nabriva Therapeutics<\/li>\n<li>Bayer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pyelonephritis Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Contepo<\/li>\n<li>Tebipenem HBr (SPR994)&nbsp;<\/li>\n<li>Cefepime-Enmetazobactam\/AAI101<\/li>\n<li>Cefepime\/taniborbactam<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many more.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pyelonephritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pyelonephritis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Pyelonephritis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Pyelonephritis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Pyelonephritis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Pyelonephritis Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Pyelonephritis Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Pyelonephritis Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Pyelonephritis Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the Pyelonephritis Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Pyelonephritis Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Pyelonephritis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Pyelonephritis Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Pyelonephritis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pyelonephritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/pyelonephritis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Graves Orbitopathy Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Graves Orbitopathy Market Research Report present a detailed analysis of the market listing Graves Orbitopathy Epidemiology, Drug therapies and pipeline for study period from 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pyelonephritis-therapeutic-analysis-insights-into-fda-and-eu-approvals-clinical-trials-latest-breakthroughs-emerging-therapies-and-key-companies-bayer-venatorx-nabriva-spero-shionogi\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pyelonephritis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/pyelonephritis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/pyelonephritis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pyelonephritis-therapeutic-analysis-insights-into-fda-and-eu-approvals-clinical-trials-latest-breakthroughs-emerging-therapies-and-key-companies-bayer-venatorx-nabriva-spero-shionogi\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pyelonephritis Therapeutics As per DelveInsight, the Pyelonephritis Market dynamics is expected to transform in the coming years owing to the expected launch of the therapies. The increasing awareness related to urinary tract infections including pyelonephritis will also boost the pyelonephritis &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pyelonephritis-therapeutic-analysis-insights-into-fda-and-eu-approvals-clinical-trials-latest-breakthroughs-emerging-therapies-and-key-companies-bayer-venatorx-nabriva-spero-shionogi_611309.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-611309","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=611309"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611309\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=611309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=611309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=611309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}